Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| [(2S,6R)-6-{N4-Benzoylcydin-1-yl}-4-tritylmorpholin-2-yl]methyl dimethyl-phosphoramidochloridate | This product is a potent inhibitor of Abl kinases and was developed for the treatment of chronic myeloid leukemia (CML). It works by blocking the activity of the Bcr-Abl fusion protein, which drives the growth of CML cells. Clinical trials have shown promising results, with high rates of complete remission and durable responses in patients with CML who were resistant or intolerant to previous treatments. Group: Pharmaceutical. CAS No. 956139-21-2. Pack Sizes: 1 g. Product ID: B2706-339313. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| Abl Cytosolic Substrate | Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl). Group: Pharmaceutical. CAS No. 168202-46-8. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-016269. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abl Cytosolic Substrate acetate | Abl Cytosolic Substrate acetate is a substrate for Abelson tyrosine kinase (Abl). Group: Pharmaceutical. CAS No. 2918768-10-0. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-016268. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Asciminib | Asciminib, also known as ABL-001, is a potent and selective allosteric Bcr-Abl inhibitor. Asciminib inhibits Ba/F3 cell growth with an IC50 of 0.25 nM. Uses: Tyrosine kinase inhibitors. Group: Pharmaceutical. CAS No. 1492952-76-7. Pack Sizes: 10 mg. Product ID: B0084-007699. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AT9283 | AT-9283 is a broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50= 3, 3, 1.2, 1.1, and 4 nM, respectively). It also potently (IC50 = <1 μM) inhibits serine/threonine kinases as well as receptor and non-receptor tyrosine kinases. Group: Pharmaceutical. CAS No. 896466-04-9. Pack Sizes: 10 mg. Product ID: B0084-100114. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Dasatinib | Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. Group: Pharmaceutical. CAS No. 302962-49-8. Pack Sizes: 25 g. Product ID: NP3264. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyl Imatinib-[d8] | N-Desmethyl Imatinib-[d8] is a deuterated metabolite of gleevec, a tyrosine kinase inhibitor specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Group: Pharmaceutical. CAS No. 1185103-28-9. Pack Sizes: 5 mg. Product ID: BLP-009648. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Nilotinib monohydrochloride monohydrate | Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. It also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). Uses: Tyrosine kinase inhibitors. Group: Pharmaceutical. CAS No. 923288-90-8. Pack Sizes: 100 mg. Product ID: B0084-182383. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| PD-173955 | PD-173955 is a src tyrosine kinase inhibitor. PD173955 inhibited Bcr-Abl-dependent cell growth. PD173955 showed cell cycle arrest in G(1). PD173955 has an IC(50) of 1-2 nM in kinase inhibition assays of Bcr-Abl, and in cellular growth assays it inhibits Bcr-Abl-dependent substrate tyrosine phosphorylation. PD173955 inhibited kit ligand-dependent c-kit autophosphorylation (IC(50) = approximately 25 nM) and kit ligand-dependent proliferation of M07e cells (IC(50) = 40 nM) but had a lesser effect on interleukin 3-dependent (IC(50) = 250 nM) or granulocyte macrophage colony-stimulating factor (IC(50) = 1 microM)-dependent cell growth. Group: Pharmaceutical. CAS No. 260415-63-2. Pack Sizes: 10 mg. Product ID: B0084-088782. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ponatinib hydrochloride | Ponatinib hydrochloride is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. It has potential antiangiogenic and antineoplastic activities. It inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. It inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). It was developed by Ariad Pharm and has been listed. Uses: Ponatinib hydrochloride is an oral drug for the treatment of chronic myeloid leukemia (cml) and philadelphia chromosome-positive (ph+) acute lymphoblastic leukemia (all). it has potential antiangiogenic and antineoplastic activities. Group: Pharmaceutical. CAS No. 1114544-31-8. Pack Sizes: 300 mg. Product ID: B0084-475072. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Radotinib | Radotinib, also known as IY-5511, is an orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways. The inhibitory effect of radotinib on these specific tyrosine kinases may decrease cellular proliferation and inhibit angiogenesis. This agent has shown potent efficacy in CML cells that are resistant to the first-generation standard tyrosine kinase inhibitors, such as imatinib, nilotinib and dasatinib. PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. Check for active clinical trials or closed clinical trials using this agent. Group: Pharmaceutical. CAS No. 926037-48-1. Pack Sizes: 50 mg. Product ID: B0084-465339. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Saracatinib | Saracatinib, also known as AZD0530, is an orally available dual-specific inhibitor of Src and Abl with anti-invasive and anti-tumor activities. Src and Abl are protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. Saracatinib binds to and inhibits these tyrosine kinases and their effects on cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption. Uses: Antineoplastic agents. Group: Pharmaceutical. CAS No. 379231-04-6. Pack Sizes: 100 mg. Product ID: B0084-067564. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
